TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03521557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaze and Postural Stability
Description: The duration and content of the GPS intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care Control
Description: The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Control
Description: The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength.
Study: NCT02198638

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: A nasal swab
Description: A nasal swab was performed by a research assistant and influenza virus infection was confirmed by enzyme-linked immunosorbent assay and reverse transcription-polymerase chain reaction on viral cultures
Study: NCT01940965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lixisenatide AVE0010
Description: Pharmaceutical form:solution Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lixisenatide AVE0010
Description: Pharmaceutical form:solution Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lixisenatide AVE0010
Description: Pharmaceutical form:solution Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lixisenatide AVE0010
Description: Pharmaceutical form:solution Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biguanide
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZD
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-GI
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glinide
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT00073918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 tositumomab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo ASCT given via central catheter
Study: NCT04577105

Intervention type: DIAGNOSTIC_TEST
Intervention: Simple chest tomography
Description: The images were acquired with a Siemens 256-slice multidetector tomograph (SOMATOM DEFINITION FLASH 128x2) following the recommended parameters for low-dose simple chest tomography. The chest topogram was acquired using 35 mA, 100 Kv, and 6 mm slices, then the chest tomographic slices holding inspiration in a cephalocaudal direction with 80 mA, 100 Kv, a duration of 2.24 seconds, a pitch of 1, and slices 1 mm with a total of 110 DLP, which is calculated with the conversion factor for thorax a total of 1.5 mSv. Multiplanar reconstructions with Kernel filters B26f, B50f, and B70 for mediastinum and lung, respectively, at 1 mm slices.
Study: NCT03654417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA
Description: Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
Study: NCT02980081

Intervention type: OTHER
Intervention: abdominal plain x-ray
Description: Abdominal plain x-ray as prescribed by the emergency physician
Study: NCT01706562

Intervention type: DRUG
Intervention: Itraconazole
Description: Itraconazole intravenous (IV) 200 mg twice daily for 2 days, a total of 4 doses and then 200 mg once daily until clinically significant resolution of neutropenia.
Study: NCT00003039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Study: NCT01471977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education,counseling, default tracers,quality of care
Description: these interventions were administered along with standard treatment i.e. DOTS at the time of standard follow up of patients at clinic
Study: NCT05418803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHP1807 Tab. 2.5mg
Description: Rivaroxaban 2.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YHP1807 Tab. 2.5mg
Description: Rivaroxaban 2.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1901 Tab. 2.5mg
Description: Rivaroxaban 2.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YHR1901 Tab. 2.5mg
Description: Rivaroxaban 2.5mg
Study: NCT01585883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management Intervention
Description: Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session. The intervention is delivered through scheduled home visits (7 sessions about one-hour in length), telephone coaching (2 sessions/week to reinforce use of strategies and for symptom monitoring: 15 minutes), and nurse moderated online peer chat or chat that is self-initiated at other times (7 weekly sessions about one hour in length).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-management Intervention
Description: Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session. The intervention is delivered through scheduled home visits (7 sessions about one-hour in length), telephone coaching (2 sessions/week to reinforce use of strategies and for symptom monitoring: 15 minutes), and nurse moderated online peer chat or chat that is self-initiated at other times (7 weekly sessions about one hour in length).
Study: NCT01407016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole IV 500 mg
Description: On Day 1, subjects will receive a single dose of 500 mg metronidazole by intravenous infusion over 20 minutes. On Day 3 to Day 7, subjects will receive multiple doses of 500 mg metronidazole by intravenous infusion over 20 minutes 4 times a day (every 6 hours) for 5 days.
Study: NCT01324947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity
Study: NCT00763360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DisCoVisc®
Description: Injection of DisCoVisc® Ophthalmic Viscosurgical Device (OVD) into the anterior chamber prior to and throughout the cataract surgery procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Healon
Description: Injection of Healon into the anterior chamber prior to and throughout the cataract surgery procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amvisc Plus
Description: Injection of Amvisc Plus into the anterior chamber prior to and throughout the cataract surgery procedure
Study: NCT04724746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure and Cognitive Behavioral Therapy
Description: Intervention involves writing details about a recent sexual assault and coping skills for substance use.
Study: NCT02832778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenz 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenz 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir /emtricitabine
Description: tenofovir 245 mg/emtricitabine 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir /emtricitabine
Description: tenofovir 245 mg/emtricitabine 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir/lamivudine
Description: tenofovir 245mg/lamivudine 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir/lamivudine
Description: tenofovir 245mg/lamivudine 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine/zidovudine
Description: lamivudine 300mg/zidovudine 600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine/zidovudine
Description: lamivudine 300mg/zidovudine 600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifinah or local generics
Description: Rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if \<50kg.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifinah or local generics
Description: Rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if \<50kg.)
Study: NCT04102137

Intervention type: BIOLOGICAL
Intervention: Pertagen (aP BioNet)
Description: Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region.

Intervention type: BIOLOGICAL
Intervention: Boostagen (TDaP BioNet)
Description: Boostagen (TDaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TDaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region.

Intervention type: BIOLOGICAL
Intervention: Adacel
Description: Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region.
Study: NCT04042584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visio conference device evaluation (DVCM)
Description: Standard neurological tele-evaluation (limited to 15minutes) remotely carried out by a first neurologist via a tablet (DVCM) and an operator. A second neurologist assist at the assessment without intervention next to the patient. Once the remote assessment is complet, the second neurologist ensure the continuation of standard patient care.
Study: NCT00598728

Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionaires
Description: A patient questionnaire, which includes questions on medical morbidities and QOL, will be mailed to participants.
Study: NCT03323593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: blood is sampled for quantification of plasma concentration after intravenous, intranasal by atomisation and intranasal by drops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: blood is sampled for quantification of plasma concentration after intravenous, intranasal by atomisation and intranasal by drops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: blood is sampled for quantification of plasma concentration after intravenous, intranasal by atomisation and intranasal by drops.
Study: NCT04472221

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterioarterial synthetic graft
Description: Synthetic poly tetraflouroethylene graft
Study: NCT02823470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Description: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Description: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: activated smart device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: de-activated smart device
Study: NCT04356157

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioural change interventions
Description: The study evaluates three different interventions aimed at improving adherence and retention to Anti Retroviral therapy among HIV positive women through engagement with their life partner. The interventions are 1) opening the facility once a month, only for men, special day; 2) testing peer-to-peer counselling among men, male champions; 3) providing incentive to all women accompanied by their partners at the facility, nudge or incentive.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioural change interventions
Description: The study evaluates three different interventions aimed at improving adherence and retention to Anti Retroviral therapy among HIV positive women through engagement with their life partner. The interventions are 1) opening the facility once a month, only for men, special day; 2) testing peer-to-peer counselling among men, male champions; 3) providing incentive to all women accompanied by their partners at the facility, nudge or incentive.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioural change interventions
Description: The study evaluates three different interventions aimed at improving adherence and retention to Anti Retroviral therapy among HIV positive women through engagement with their life partner. The interventions are 1) opening the facility once a month, only for men, special day; 2) testing peer-to-peer counselling among men, male champions; 3) providing incentive to all women accompanied by their partners at the facility, nudge or incentive.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioural change interventions
Description: The study evaluates three different interventions aimed at improving adherence and retention to Anti Retroviral therapy among HIV positive women through engagement with their life partner. The interventions are 1) opening the facility once a month, only for men, special day; 2) testing peer-to-peer counselling among men, male champions; 3) providing incentive to all women accompanied by their partners at the facility, nudge or incentive.
Study: NCT03594929

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active RIC

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Study: NCT02365662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-221
Description: ABBV-221 will be given either every 3 weeks or 2 weeks on, 1 week off or weekly dosing by intravenous infusion approximately over 30 minutes to 3 hours. This is a dose escalation study, therefore the dose of ABBV-221 will change throughout the study.
Study: NCT05108766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Description: Tildrakizumab 100 mg administered SC. Each PFS contains 1 mL of solution, tildrakizumab 100 mg/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to tildrakizumab administered SC
Study: NCT02548286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan 8mg
Description: PO, 1day or 22day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5mg
Description: PO, 1day or 22day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 8/5mg
Description: PO, 1day or 22day
Study: NCT04255199

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Clinicians randomized to the control group will receive a single visit with a standardized patient instructor (SPI) scheduled during usual office hours. SPIs will portray a patients with acute back pain but will deliver no formative training or feedback to the primary care physicians randomized to the control arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Clinicians randomized to the intervention group will receive 2-3 visits with a standardized patient instructor (SPI) scheduled during usual office hours over \~3 month period. For intervention physicians, SPIs will portray patients with acute back pain and will provide formative feedback to physicians and specific instruction in communication techniques to facilitate patient acceptance of a watchful waiting strategy with respect to spinal imaging. The specific communication techniques and sequence will be determined based on pre-trial literature review, patient focus groups, and interviews of primary care physicians who will not participate in the trial.
Study: NCT00993005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cicatrix
Description: Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
Study: NCT06155188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: applying of FLU+CY post-HSCT
Description: The conditioning regimen (PT-Cy/Flu group) consisted of fludarabine (40mg/m2, d-5 to d-3 and d+3, d+4), busulfan (100mg/m2, d-6 to d-3), haplo-PBSC (d0), PTCy (50mg/kg, d+3, d+4) and UCB (d+6).
Study: NCT01123070

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TL011, anti CD20, for the treatment of rheumatoid arthritis
Description: TL011 administered by 2 infusions, 2 weeks apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MabThera infusions
Description: MabThera, administered by 2 infusions, 2 weeks apart
Study: NCT02696876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthroscopic synovial brushing
Description: The specific and novel surgical procedure that will be carried out here is synovial membrane brushing using a novel device that has been shown to release MSCs from the synovium in vitro. This technique will be carried out in the setting of therapeutic microfracture for cartilage defects.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Microfracture or marrow-stimulation is a surgical procedure to repair small isolated cartilage defects by recruiting bone marrow mesenchymal stromal cells by creating small holes ('micro fractures') in the sub-chondral bone. These cells are entrapped in the ensuing blood clot and contribute to partial repair of the cartilage.
Study: NCT00282672

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation System plus anti-secretory medication
Description: Treatment group subjects undergo up to 4 ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation System plus anti-secretory medication
Description: Treatment group subjects undergo up to 4 ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure plus anti-secretory medication
Description: The Sham Control group undergo an upper endoscopy procedure with sizing of the esophageal diameter (a component of the ablation procedure steps, deemed the sham procedure) plus standard anti-secretory drug therapy (Proton pump inhibitor, PPI)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure plus anti-secretory medication
Description: The Sham Control group undergo an upper endoscopy procedure with sizing of the esophageal diameter (a component of the ablation procedure steps, deemed the sham procedure) plus standard anti-secretory drug therapy (Proton pump inhibitor, PPI)
Study: NCT02575716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolaryngoscope
Description: Intubation with McGrath video laryngoscope after muscle relaxant

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Videolaryngoscope
Description: Intubation with McGrath video laryngoscope after muscle relaxant
Study: NCT01715662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wii.n.Walk
Description: Subjects will be trained using Nintendo Wii Fit (commercial fitness gaming software) for 40-minute sessions, 3x/week for 4 weeks. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wii Big Brain
Description: Subjects in the control group will be trained using Wii Big Brain Academy Degree program which is a low-cost commercially available gaming software to improve cognitive function. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
Study: NCT01325311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genistein
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT01696552

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKR with Positioning Guides (PSPG)
Description: TKR (Vanguard Total Knee System, Biomet) with PSPG (Signature, Materialise) technique